全文获取类型
收费全文 | 130219篇 |
免费 | 9760篇 |
国内免费 | 229篇 |
专业分类
耳鼻咽喉 | 1186篇 |
儿科学 | 3642篇 |
妇产科学 | 2713篇 |
基础医学 | 20494篇 |
口腔科学 | 3332篇 |
临床医学 | 11115篇 |
内科学 | 26367篇 |
皮肤病学 | 2224篇 |
神经病学 | 12750篇 |
特种医学 | 5228篇 |
外国民族医学 | 10篇 |
外科学 | 16226篇 |
综合类 | 557篇 |
现状与发展 | 1篇 |
一般理论 | 106篇 |
预防医学 | 14946篇 |
眼科学 | 2035篇 |
药学 | 7810篇 |
中国医学 | 261篇 |
肿瘤学 | 9205篇 |
出版年
2023年 | 567篇 |
2022年 | 951篇 |
2021年 | 2081篇 |
2020年 | 1486篇 |
2019年 | 2163篇 |
2018年 | 2713篇 |
2017年 | 2296篇 |
2016年 | 2503篇 |
2015年 | 2811篇 |
2014年 | 3816篇 |
2013年 | 5026篇 |
2012年 | 7704篇 |
2011年 | 7821篇 |
2010年 | 4060篇 |
2009年 | 4229篇 |
2008年 | 6913篇 |
2007年 | 7132篇 |
2006年 | 6865篇 |
2005年 | 6518篇 |
2004年 | 5622篇 |
2003年 | 5287篇 |
2002年 | 4827篇 |
2001年 | 4480篇 |
2000年 | 4420篇 |
1999年 | 3957篇 |
1998年 | 1648篇 |
1997年 | 1364篇 |
1996年 | 1436篇 |
1995年 | 1168篇 |
1994年 | 1093篇 |
1993年 | 995篇 |
1992年 | 2705篇 |
1991年 | 2431篇 |
1990年 | 2311篇 |
1989年 | 2145篇 |
1988年 | 1964篇 |
1987年 | 1721篇 |
1986年 | 1629篇 |
1985年 | 1565篇 |
1984年 | 1136篇 |
1983年 | 978篇 |
1982年 | 537篇 |
1981年 | 470篇 |
1980年 | 412篇 |
1979年 | 876篇 |
1978年 | 534篇 |
1977年 | 430篇 |
1974年 | 419篇 |
1973年 | 415篇 |
1972年 | 369篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
91.
H Hultgren P Peduzzi W Shapiro D van Heeckeren 《Progress in cardiovascular diseases》1986,28(4):279-284
92.
Donor interleukin-4 promoter gene polymorphism influences allograft rejection after heart transplantation. 总被引:3,自引:0,他引:3
Femke J Bijlsma Joyce vanKuik Marcel G J Tilanus Nicolaas deJonge Erik H Rozemuller Jan G van den Tweel Frits H J Gmelig-Meyling Roel A deWeger 《The Journal of heart and lung transplantation》2002,21(3):340-346
BACKGROUND: The cytokine interleukin-4 (IL-4) is secreted mainly by activated T lymphocytes and characterizes the T-helper 2 (Th2) sub-type. In transplantation Th2 cells are believed to induce graft tolerance. Previous studies revealed that patients with a relatively high frequency of IL-4 producing helper T lymphocytes (HTL) before heart transplantation (HTX) had no or less rejection episodes compared with patients with a low frequency of IL-4 producing HTL. Three single nucleotide polymorphisms (SNPs) have been identified in the promoter region of the IL-4 gene, which influence promoter strength. We investigated whether there was a correlation between SNP genotypes in the IL-4 promoter and heart failure, and rejection after HTX. METHODS: Seventy HTX patients, 61 donors, and 36 controls were genotyped for the 3 SNPs by sequencing. RESULTS: Of the SNPs at -285 and -81, only the C and A alleles, respectively, were found in this study. Both alleles were found for the -590 SNP. No relation between patient genotype of the SNP at -590 and heart failure and rejection was found. However, incidence of rejection was significantly lower in patients that received a donor heart with the T-positive genotype compared with patients that received a heart from a T-negative donor. Patients who had the T-negative genotype and received a heart from a T-positive donor, suffered significantly less from rejection than T-negative patients that received a T-negative donor heart. This was not significant in the T-positive patient group. CONCLUSIONS: This indicates that IL-4 production within the donor heart and by cells from the donor is important for reducing incidence of episodes of rejection. 相似文献
93.
94.
The diagnosis of albinism is indicated by the presence of visual pathway misrouting in which temporal retinal fibers erroneously decussate at the optic chiasm disrupting the normal topographical distribution of retinal geniculate-cortical projections. Detection of misrouted fibers is effected by non-invasive electrophysiological assessment of the topographical representation of the visual evoked potential (VEP) following full field monocular stimulation. By combining appropriate state defined neonatal recording procedures with the albino VEP test paradigm, the presence of aberrant optic pathway projections was detected in a five-day-old full-term infant. The electrophysiological signature pathognomonic to albinism was observed within a long (300 ms) latency window of an otherwise normal neonatal luminance flash response. The results of this study indicate that the VEP misrouting test can be extended to reliable albino diagnosis within the neonatal period. 相似文献
95.
96.
C E Hack J Wagstaff R J Strack van Schijndel A J Eerenberg H M Pinedo L G Thijs J H Nuijens 《Thrombosis and haemostasis》1991,65(5):497-503
Patients treated with high doses of interleukin-2 (IL-2) because of cancer, develop hemodynamic and vasopermeability changes, that resemble those observed in sepsis. These patients thus provide a unique opportunity to study the early events in the development of septic shock. We analysed the changes that occurred in the contact system of coagulation in plasma from 4 patients, who together received seven 12-day cycles of high doses of IL-2. Levels of factor XII and prekallikrein during the cycles progressively fell to 50 and 30% of their initial levels, respectively, whereas significant increases in plasma factor XIIa- and kallikrein-C1-inhibitor complexes were not observed (in 3 out of 211 samples slightly increased levels of both complexes were found). The reductions in factor XII and prekallikrein were only in part due to protein leakage, since levels were still significantly lower, i.e., 80 and 50%, respectively, when corrected for albumin decreases. Levels of high molecular weight kininogen (HMWK) also decreased during IL-2 therapy, however, this decrease paralleled that of albumin. SDS-PAGE analysis of plasma HMWK did not reveal increased cleavage of this protein. The reduction of factor XII and prekallikrein, corrected for protein leakage, significantly correlated with albumin levels and inversely with daily cumulative weight gain in the patients. Thus, we demonstrate that factor XII and prekallikrein decrease during IL-2 therapy. As these decreases, already observed after 1 day treatment, were disproportional to that of albumin, a negative acute phase reactant, and correlated with signs of the vascular leak syndrome, we favor the explanation that they reflected activation rather than a decreased synthesis of the contact system proteins.(ABSTRACT TRUNCATED AT 250 WORDS) 相似文献
97.
L M van Wijk P den Heijer H J Crijns W H van Gilst K I Lie 《Journal of cardiovascular pharmacology》1989,13(1):32-36
We compared the efficacy of flecainide versus quinidine in preventing paroxysms of atrial fibrillation in a randomized open crossover study. Twenty-six patients with weekly attacks of atrial fibrillation during the last 3 months, objectified by 24-h holter monitoring or 12-lead electrocardiogram (ECG) were treated for a period of 3 months with flecainide 100 mg b.i.d. or quinidine 500 mg b.i.d. Efficacy was assessed by 24-h holter monitoring and a questionnaire at the end of each month. Dosage was adjusted to flecainide 100 mg t.i.d. or quinidine 500 mg t.i.d. if patients still had symptomatic paroxysms of atrial fibrillation according to a questionnaire or on holter monitoring. In 46% of the patients, flecainide 100 mg b.i.d. caused total abolition of supraventricular tachycardia; after dose adjustment it caused 50% total abolition. For quinidine, the figures are 16% (p less than 0.05) and 32% (NS), respectively. Side effects occurred with flecainide only after dose adjustment (23%), but on quinidine they occurred before (8%) and after dose adjustment (20%). We conclude that flecainide suppresses paroxysms of atrial fibrillation significantly more often as compared with quinidine in the lower dosage regimen. Optimal treatment dosage of flecainide is 100 mg b.i.d. After quinidine dose adjustment, the difference in efficacy is no longer significant. However, side effects necessitating discontinuation of quinidine developed in 20% of the patients as compared to none in patients treated with flecainide 100 mg b.i.d. 相似文献
98.
Alcoholic liver disease: an IgA-associated disorder 总被引:1,自引:0,他引:1
99.
Mo Weijtens Anke van Spronsen Anton Hagenbeek Eric Braakman Anton Martens 《Human gene therapy》2002,13(2):187-198
Graft-versus-host disease (GvHD), a major complication of allogeneic bone marrow transplantation, has been ascribed to mature T cells in the graft. Because T cells play an important role in engraftment of the bone marrow and decrease the probability of relapse of leukemia, a treatment strategy was developed to preserve the benefits of T cells in the graft and to control the severe complications of GvHD. This can be accomplished by the genetic modification of donor T cells with a suicide gene that allows their selective in vivo elimination and subsequently the abrogation of GvHD. For clinical benefit the alloreactivity of herpes simplex virus thymidine kinase (HSV-TK) gene-transduced T cells should be retained. Therefore, we investigated the influence of gene transduction and the selection procedure on T cells. We demonstrated that activation and culturing of T cells reduce their capacity to induce lethal GvHD in an allogeneic rat bone marrow transplantation model. Furthermore, positive immunomagnetic selection of gene-transduced T cells resulted in loss of the GvHD-inducing capacity of HSV-TK(+) T cells directly after MACS (magnetic cell sorting) selection; this loss could be recovered by a 1-day expansion of the selected T cells. No effect on alloreactivity was observed to be caused by the gene transduction procedure. Our study resulted in the development of an optimized culture and gene transduction protocol with preservation of T cell alloreactivity. Treatment of transplanted rats with ganciclovir resulted in a rapid reduction in the number of HSV-TK(+) T cells in the peripheral blood and in increased survival of the animals. 相似文献